Penn gene therapy spinout taking on rare retinal diseases launches with $19M in seed funding
A new gene therapy company attempting to commercialize the research of Penn Medicine's Dr. Jean Bennett launched Wednesday in North Carolina with $19 million in seed capital. The company, Opus Genetics, is the first spinout company internally conceived and launched by the Retinal Degeneration Fund (RD Fund), the venture arm of the Foundation Fighting Blindness. The fund was created to further the foundation's mission of backing research to prevent, treat and cure retin al degenerative diseases. Opus… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 22, 2021 Category: American Health Authors: John George Source Type: news

Gene Therapy Research Accelerates for Retinal Diseases Gene Therapy Research Accelerates for Retinal Diseases
Patients who have rare retinal diseases — as well as those with more common ones — may benefit from a surge in gene therapy research.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 17, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presentation at t...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How Many Inherited Retinal Diseases Are There?
Title: How Many Inherited Retinal Diseases Are There?Category: Diseases and ConditionsCreated: 9/2/2021 12:00:00 AMLast Editorial Review: 9/2/2021 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - September 2, 2021 Category: Opthalmology Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Is Retinol Good for Aging Skin?
Title: Is Retinol Good for Aging Skin?Category: Health and LivingCreated: 8/5/2021 12:00:00 AMLast Editorial Review: 8/5/2021 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - August 5, 2021 Category: Dermatology Source Type: news

FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) ...
Source: Roche Investor Update - July 29, 2021 Category: Pharmaceuticals Source Type: news

FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) ...
Source: Roche Media News - July 29, 2021 Category: Pharmaceuticals Source Type: news

Golden Rice: Triumph for Science
By Paul TengSINGAPORE, Jul 28 2021 (IPS) After almost two decades, Golden Rice was approved last week by the Philippines authorities for use as food. This together with the approval of the bioengineered Bt eggplant represents a landmark victory of science over misinformation; it will provide consumers with improved nutrition (Golden Rice) and safer food (Bt eggplant). Paul TengBIOTECHNOLOGY CROPS have been controversial in spite of overwhelming support for their safety by the scientific community. This is specially so for the class of biotechnology crops commonly called ‘GMO’ or genetically modified organism. The cont...
Source: IPS Inter Press Service - Health - July 28, 2021 Category: International Medicine & Public Health Authors: Paul Teng Tags: Asia-Pacific Biodiversity Climate Change Economy & Trade Environment Food & Agriculture Food Security and Nutrition Headlines Health TerraViva United Nations Source Type: news

Healthy Directions and Whitaker Nutrition launch new one-a-day...
Healthy Directions and Whitaker Nutrition launch one-a-day vegetarian Vision Essentials ULTRA supplement that brings important new benefits to the growing issues surrounding healthy vision, retinal...(PRWeb July 26, 2021)Read the full story at https://www.prweb.com/releases/healthy_directions_and_whitaker_nutrition_launch_new_one_a_day_vegetarian_vision_essentials_ultra_supplement_for_comprehensive_eye_support/prweb18091486.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 26, 2021 Category: Pharmaceuticals Source Type: news

Retinal Activity Prepares Blind Newborn Mice for Vision
Spontaneous waves of nerve impulses flowing across the retina help mouse pups practice motion detection for when they eventually open their eyes. (Source: The Scientist)
Source: The Scientist - July 22, 2021 Category: Science Tags: News & Opinion Source Type: news

What Problems are Ciliopathies Associated With?
Discussion Nephronophthisis (NPHP) one cause of end-stage renal disease (ESRD) usually occurring before age 30 years. NPHP is a non-motile ciliopathy affecting cellular sensing in the renal tubular epithelium. See To Learn More below. The incidence varies according to location with 1:1 million in the US but 1:50,000 in Finland. There are 3 subtypes: Infantile Occurs usually within 1 year of life Enlarged kidneys and severe hypertension In utero can have oligohydramnios problems such as pulmonary hypoplasia, facial dysmorphisms, limb contractures Extra-renal problems include congenital heart disease, liver fibrosis, recur...
Source: PediatricEducation.org - July 5, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roughness of retinal layers, a new Alzheimer's biomarker
(Universidad Complutense de Madrid) Researchers at the Universidad Complutense de Madrid and Hospital Cl í nico San Carlos have designed a mathematical method to measure this. In some layers, wrinkling begins at very early stages of the illness. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 23, 2021 Category: International Medicine & Public Health Source Type: news

Vitamin B12 deficiency: Have you felt this peculiar sensation in your thighs? Sign to spot
VITAMIN B12 is so integral for the proper functioning of the body when a person lacks in the essential vitamin a variety of peculiar signs may develop. Feeling a certain sensation along the back of the thighs could indicate a serious deficiency. (Source: Daily Express - Health)
Source: Daily Express - Health - June 19, 2021 Category: Consumer Health News Source Type: news